Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT06854445 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT06854445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
February 29, 2028
Enrollment
55 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large cell b-lymphoma